Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents, Patent Applications Awarded to Alnylam; Medtronic; IBM; and More


Title: Method and Medicament for Inhibiting the Expression of a Given Gene

Patent Number: 8,119,608

Filed: March 6, 2003

Lead Inventor: Roland Kreutzer, Alnylam Pharmaceuticals

The invention, the patent's abstract states, “provides methods and compositions for inhibiting gene expression using double-stranded RNA molecules that are between 15 and 24 nucleotides in length and are complementary to a target gene sequence.”

Title: Method for Efficient RNA Interference in Mammalian Cells

Patent Number: 8,119,610

Filed: May 29, 2003

Lead Inventor: Dun Yang, University of California, Oakland

The invention relates to “methods of making RNAi libraries using E. coli RNAse III for inhibition of mammalian gene expression,” the patent's abstract states.

Title: Treatment of Neurodegenerative Disease Through Intracranial Delivery of siRNA

Patent Number: 8,119,611

Filed: Aug. 27, 2009

Inventor: William Kaemmerer, Medtronic

The invention comprises “devices, small interfering RNA, and methods for treating a neurodegenerative disorder … [by] surgically implanting a catheter so that a discharge portion of the catheter lies adjacent to a predetermined infusion site in a brain, and discharging through the discharge portion of the catheter a predetermined dosage of at least one substance capable of inhibiting production of at least one neurodegenerative protein,” the patent's abstract states. The invention also “provides valuable small interfering RNA vectors and methods for treating neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, spinocerebellar ataxia type 1, type 2, type 3, and/or dentatorubral-pallidoluysian atrophy.”

Title: RNAi Inhibition of Alpha-EnaC Expression

Patent Number: 8,119,612

Filed: April 30, 2010

Lead Inventor: Gino Van Heeke, Novartis

“The invention relates to compositions and methods for modulating the expression of alpha-ENaC and, more particularly, to the down-regulation of alpha-ENaC expression by chemically modified oligonucleotides,” the patent's abstract states.

Title: siRNA-Mediated Gene Silencing Technology to Inhibit Tyrosinase and Reduce Pigmentation

Patent Number: 8,119,791

Filed: Jan. 29, 2009

Lead Inventor: Ralph Binetti, Avon Products

The invention, the patent's abstract states, comprises “compositions and methods for treating, preventing, and improving hyperpigmentation or [eliminating] unwanted pigmentation of the skin or other unwanted skin condition, such as age spots, aged skin, skin discoloration, etc.”

The compositions include siRNA ... specific for tyrosinase … [and] are used to treat a broad variety of pigmentation conditions, and are preferably applied to the skin, or are delivered by directed means to a site in need thereof,” the abstract adds.

Title: Compositions and Methods for siRNA Inhibition of Angiopoietin 1 and 2 and Their Receptor Tie2

Application Number: 20120039986

Filed: June 20, 2011

Lead Inventor: Samuel Reich, University of Pennsylvania (Opko Health)

The invention, the patent application's abstract states, relates to “RNA interference using small interfering RNAs, which are specific for mRNA produced from the Ang1, Ang2, or Tie2 genes [and inhibit] expression of these genes. Diseases which involve Ang1-, Ang2-, or Tie2-mediated angiogenesis, such as inflammatory and autoimmune diseases, diabetic retinopathy, age-related macular degeneration, and many types of cancer, can be treated by administering the small interfering RNAs.”

Title: Reduced Size Self-Delivering RNAi Compounds

Application Number: 20120040459

Filed: Sept. 22, 2009

Lead Inventor: Anastasia Khvorova, RXi Pharmaceuticals

The invention, the patent application's abstract states, relates to “RNAi constructs with minimal double-stranded regions and their use in gene silencing. RNAi constructs associated with the invention include a double-stranded region of 8 [to] 14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing.”

Title: Ribonucleic Acid Interference Molecules

Application Number: 20120040460

Filed: Oct. 27, 2011

Lead Inventor: Isidore Rigoutsos, International Business Machines

The invention, the patent application's abstract states, comprises “ribonucleic acid interference molecules.”

Title: miRNA Targets

Application Number: 20120040851

Filed: Sept. 18, 2009

Lead Inventor: Judy Lieberman, Harvard University

The invention provides “systems for identifying, isolating, and/or characterizing targets of microRNAs,” according to the patent application's abstract.

Title: Compositions and Methods Relating to miR-31

Application Number: 20120041048

Filed: Dec. 7, 2009

Lead Inventor: Robert Weinberg, Whitehead Institute for Biomedical Research

The patent application, its abstract states, claims “microRNA-31, targets of miR-31, the role of miR-31 in inhibiting tumor metastasis, and the role of miR-31 target genes in promoting tumor metastasis.”

Title: Design of Small Interfering RNA

Application Number: 20120041049

Filed: Feb. 24, 2010

Inventor: Jacques Rohayem, Riboxx

The invention, the patent application's abstract states, “relates to small-interfering RNA molecules displaying an increased thermodynamic stability at the 3' end of the antisense strand and the 5' end of the sense strand, respectively, in comparison to the base pairing in the seed region. The siRNAs of the ... invention display an increased knockdown activity against targeted genes and show an improved resistance to RNAses, in particular serum RNAses. The ... invention also relates to a method for the production of the siRNA molecules, a method of target-specific RNA interference making use of the improved siRNA molecules of the invention, and pharmaceutical compositions containing the siRNA molecules.”

Title: Compositions and Methods for Inhibiting Expression of MIG-12 Gene

Application Number: 20120041051

Filed: Feb. 25, 2010

Lead Inventor: Kevin Fitzgerald, Alnylam Pharmaceuticals

“The invention relates to a double-stranded ribonucleic acid targeting MIDI interacting G12-like protein gene, and methods of using the dsRNA to inhibit expression of MIG 12,” according to the patent application's abstract.

Title: Compositions and Methods to Treat Muscular and Cardiovascular Disorders

Application Number: 20120041052

Filed: Aug. 9, 2011

Lead Inventor: Iwan Beuvink, Novartis

The invention relates to “a novel microRNA, miR-208-2, implicated in muscular and cardiovascular disorders,” the patent application's abstract states. The invention also relates to “oligonucleotide therapeutic agents and their use in the treatment of muscular and cardiovascular disorders resulting from dysregulation of miR-208-2.”

Title: RNA Interference-Mediated Inhibition of Human Immunodeficiency Virus Gene Expression Using Short Interfering Nucleic Acid

Application Number: 20120041184

Filed: July 11, 2011

Lead Inventor: Leonid Beigelman, Merck

“This invention relates to compounds, compositions, and methods useful for modulating human immunodeficiency virus gene expression using short interfering nucleic acid molecules,” the patent application's abstract states. “This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of human immunodeficiency virus gene expression and/or activity by RNA interference using small nucleic acid molecules.”

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.